Lee A G, Wagner F M, Chen M F, Serrick C, Giaid A, Shennib H
The Montreal Lung Transplant Program, Quebec, Canada.
J Thorac Cardiovasc Surg. 1998 Apr;115(4):822-7. doi: 10.1016/S0022-5223(98)70362-9.
In this study, we describe the development of a nonallogeneic animal model of obliterative bronchiolitis-like lesions. Furthermore, we examined whether chronic rejection alone can lead to the development of obliterative bronchiolitis or whether additional nonspecific airway inflammation is required.
Part I: Rats were intratracheally injected with 0.2 ml of activated charcoal or sorbitol solution (carrier for charcoal control). Animals were put to death beginning at 2 weeks up to 20 weeks. Part II: Animals were divided into three groups: group I, underimmunosuppressed Brown Norway to Lewis lung allografts; group II, charcoal-treated underimmunosuppressed allografts; and group III, charcoal-treated rats. Animals were put to death at 3 months after transplantation.
Part I: In charcoal-laden bronchioles, subacute nonspecific airway inflammation was detected at 2 weeks. Slow, subclinical fibroproliferation ensued during the following weeks. Obliterative bronchiolitis-like lesions were observed in 80% of charcoal-treated animals at 12 weeks. Part II: Allografts developed extensive vascular lesions consistent with acute and chronic vascular rejection. Obliterative bronchiolitis-like lesions were scarcely detected. Charcoal-treated allografts demonstrated evidence of diffuse and severe obliterative bronchiolitis-like lesions.
Transtracheal injection of activated charcoal into native lungs results in slowly progressive airway injury and inflammation leading to obliterative airway lesions. Inadequate immunosuppression primarily results in chronic vascular rejection but not obliterative bronchiolitis. Underimmunosuppressed allografts subjected to nonspecific airway inflammation develop obliterative airway lesions that are more prominent than in native lungs. This suggests that a cofactor to chronic rejection is likely necessary for the development of lung transplant obliterative bronchiolitis.
在本研究中,我们描述了一种闭塞性细支气管炎样病变的非同种异体动物模型的建立。此外,我们研究了单纯慢性排斥反应是否会导致闭塞性细支气管炎的发生,或者是否需要额外的非特异性气道炎症。
第一部分:给大鼠气管内注射0.2 ml活性炭或山梨醇溶液(活性炭对照载体)。从2周龄到20周龄处死动物。第二部分:将动物分为三组:第一组,免疫抑制不足的棕色挪威大鼠至刘易斯肺同种异体移植;第二组,经活性炭处理的免疫抑制不足的同种异体移植;第三组,经活性炭处理的大鼠。移植后3个月处死动物。
第一部分:在充满活性炭的细支气管中,2周时检测到亚急性非特异性气道炎症。在接下来的几周内发生缓慢的亚临床纤维增生。12周时,80%经活性炭处理的动物出现闭塞性细支气管炎样病变。第二部分:同种异体移植出现广泛的血管病变,符合急性和慢性血管排斥反应。几乎未检测到闭塞性细支气管炎样病变。经活性炭处理的同种异体移植显示出弥漫性和严重的闭塞性细支气管炎样病变的证据。
向天然肺气管内注射活性炭会导致气道损伤和炎症缓慢进展,进而导致闭塞性气道病变。免疫抑制不足主要导致慢性血管排斥反应,而非闭塞性细支气管炎。经历非特异性气道炎症的免疫抑制不足的同种异体移植会出现比天然肺更明显的闭塞性气道病变。这表明慢性排斥反应的一个辅助因素可能是肺移植闭塞性细支气管炎发生所必需的。